SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Net Income ScalingExpanding
Percentile Rank83
5Y CAGR-8.0%
Studio
Year-over-Year Change

Total earnings after all expenses, taxes, and interest

5Y CAGR
-8.0%/yr
Long-term compound
Percentile
P83
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$13.27M+138.9%
2024$-34.11M+19.2%
2023$-42.19M-125.1%
2022$-18.74M-9.3%
2021$-17.14M-185.2%
2020$20.12M+323.9%
2019$-8.99M-